Outcomes

There's this low grade buzz from some rheumatologists about the potential analgesic benefits of low dose naltrexone.  I haven't used it. Should you?

Naltrexone is FDA approved (at much higher doses) to treat alcohol dependence and to block of the effects of exogenously administered

Know-it-now

Current ACR guidelines for the management of gout support anti-inflammatory prophylaxis, including colchicine, during urate lowering therapy initiation and uptitration. Aside from diarrhea, colchicine use is generally well tolerated, but its metabolism via the CYP3A4 cytochrome P450 enzyme

Avacopan (Tavneos), the complement pathway inhibitor for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), appeared strongly effective in an Italian registry study -- a step, maybe, toward setting to rest questions about its efficacy, if not its safety.

After years of inactivity, therapeutic development for dermatomyositis has begun to move forward with several new therapies and therapeutic strategies.

"This is a very exciting time for the field because we're finally going to get some new treatments, and I think it will be helpful in

On this week's podcast, Dr. Jack Cush reviews the news: Steroids are easy to start and hard to stop; hold the MTX but not the biologic or JAK, weighing in on avacopan, and age-old messages for old-age patients. 

Close to 90% of patients with rheumatoid arthritis (RA) well controlled on targeted therapies were able to take 50% dosage reductions without experiencing worsened disease activity in a randomized trial, South Korean researchers said.

A randomized clinical trial in inflammatory arthritis arthritis shows that temporarily holding biologic or Janus kinase (JAK) inhibitor therapy at the time of COVID-19 vaccination is not warranted.